Vault-13

Lynx1 Capital Management LP

DORADO, PR · CIK 1910456 · 13F filing filed 2025-08-14

SEC-registered investment adviser since 2023 · limited partnership

As an employer

$346.2m reported value +24.0% vs Q1 2025
15positions
98.8%in top 10
1 new 6 added 0 reduced 0 sold out vs Q1 2025

This report includes the holdings of 1 other manager that shares the investment decisions:

Shares in two reports are counted once in each security's totals.

Holdings, Q2 2025

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 MERUS N V COM MRUS MRUS 1,568,841 $82.5m23.84% 23.84% UnchangedShares held: Q3 2024 1.8m, Q4 2024 1.6m, Q1 2025 1.6m, Q2 2025 1.6m
2 GH RESEARCH PLC ORDINARY SHARES GHRS GHRS 6,746,951 $82.2m23.76% 23.76% AddedShares held: Q3 2024 4.2m, Q4 2024 4.9m, Q1 2025 6.4m, Q2 2025 6.7m +303.0k +303,011 4.7%
3 STOKE THERAPEUTICS INC COM STOK STOK 5,404,674 $61.3m17.72% 17.72% AddedShares held: Q3 2024 5.2m, Q4 2024 5.2m, Q1 2025 5.3m, Q2 2025 5.4m +112.7k +112,745 2.1%
4 PROTAGONIST THERAPEUTICS INC COM PTGX PTGX 733,014 $40.5m11.70% 11.70% UnchangedShares held: Q3 2024 0, Q4 2024 0, Q1 2025 733.0k, Q2 2025 733.0k
5 CULLINAN THERAPEUTICS INC COM CGEM CGEM 4,400,842 $33.1m9.57% 9.57% AddedShares held: Q3 2024 410.8k, Q4 2024 1.3m, Q1 2025 3.2m, Q2 2025 4.4m +1.2m +1,185,120 36.9%
6 ALLOGENE THERAPEUTICS INC COM ALLO ALLO 11,057,009 $12.5m3.61% 3.61% UnchangedShares held: Q3 2024 6.2m, Q4 2024 10.9m, Q1 2025 11.1m, Q2 2025 11.1m
7 TSCAN THERAPEUTICS INC COM TCRX TCRX 7,857,347 $11.4m3.29% 3.29% AddedShares held: Q3 2024 5.2m, Q4 2024 5.4m, Q1 2025 5.4m, Q2 2025 7.9m +2.5m +2,500,000 46.7%
8 C4 THERAPEUTICS INC COM STK CCCC CCCC 7,098,133 $10.2m2.93% 2.93% UnchangedShares held: Q3 2024 6.9m, Q4 2024 6.9m, Q1 2025 7.1m, Q2 2025 7.1m
9 PRECISION BIOSCIENCES INC COM NEW DTIL DTIL 1,036,051 $4.4m1.26% 1.26% AddedShares held: Q3 2024 0, Q4 2024 766.1k, Q1 2025 766.1k, Q2 2025 1.0m +270.0k +270,000 35.2%
10 PASSAGE BIO INC COM COM 9,256,953 $3.7m1.07% 1.07% UnchangedShares held: Q3 2024 8.4m, Q4 2024 9.3m, Q1 2025 9.3m, Q2 2025 9.3m
11 UPSTREAM BIO INC COM UPB UPB 219,247 $2.4m0.70% 0.70% UnchangedShares held: Q3 2024 0, Q4 2024 240.0k, Q1 2025 219.2k, Q2 2025 219.2k
12 IBIO INC COM NEW IBIO IBIO 1,538,573 $1.2m0.34% 0.34% AddedShares held: Q3 2024 862.3k, Q4 2024 862.3k, Q1 2025 862.3k, Q2 2025 1.5m +676.3k +676,294 78.4%
13 NEUPHORIA THERAPEUTICS INC COM NEUP NEUP 45,806 $325.2k0.09% 0.09% UnchangedShares held: Q3 2024 0, Q4 2024 45.8k, Q1 2025 45.8k, Q2 2025 45.8k
14 DESIGN THERAPEUTICS INC COM DSGN DSGN 65,954 $222.3k0.06% 0.06% UnchangedShares held: Q3 2024 0, Q4 2024 0, Q1 2025 66.0k, Q2 2025 66.0k
15 ASSEMBLY BIOSCIENCES INC COM NEW ASMB ASMB 10,366 $187.8k0.05% 0.05% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 10.4k

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

CompanyTickerStakeChange ScheduleLast filed
PASSAGE BIO INC 13D · filed 2026-07-02 21.0% +1.4 pts 13D 2026-07-02
GH RESEARCH PLC GHRS · 13G · filed 2026-08-14 GHRS 19.3%≈ $354.0m +1.9 pts 13G 2026-08-14
NEUPHORIA THERAPEUTICS INC NEUP · 13D · filed 2025-12-29 NEUP 16.3%≈ $3.8m no change 13D 2025-12-29
TSCAN THERAPEUTICS INC TCRX · 13G · filed 2026-08-14 TCRX 13.1%≈ $3.4m -1.9 pts 13G 2026-08-14
KORRO BIO INC KRRO · 13G · filed 2026-04-02 KRRO 10.7%≈ $20.3m +2.9 pts 13G 2026-04-02
C4 THERAPEUTICS INC CCCC · 13G · filed 2026-08-14 CCCC 10.0%≈ $63.1m +2.7 pts 13G 2026-08-14
CULLINAN THERAPEUTICS INC CGEM · 13G · filed 2025-11-14 CGEM 9.8%≈ $105.0m -4.7 pts 13G 2025-11-14
STOKE THERAPEUTICS INC STOK · 13G · filed 2026-08-14 STOK 6.5%≈ $132.1m -1.6 pts 13G 2026-08-14
IBIO INC IBIO · 13G · filed 2026-08-14 IBIO 5.4%≈ $4.9m +5.4 pts 13G 2026-08-14
PRECISION BIOSCIENCES INC DTIL · 13G · filed 2026-07-20 DTIL 5.4%≈ $10.9m +1.3 pts 13G 2026-07-20
AGIOS PHARMACEUTICALS INC AGIO · 13G · filed 2026-05-06 AGIO 5.1%≈ $111.8m new 13G 2026-05-06

Trades reported as a company insider in Q2 2025

Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.

DateCompanyTickerTradeShares ValueTheir holding
2025-05-20 TSCAN THERAPEUTICS INC 10% owner · See footnote TCRX Bought 1,200,000 $1.4m1.2m shares +18%
2025-05-19 TSCAN THERAPEUTICS INC 10% owner · See footnote TCRX Bought 1,388,794 $1.7m1.4m shares +26%